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A fatal transmissible tumor spread between individuals by biting
has emerged in the Tasmanian devil (Sarcophilus harrisii), a car-
nivorous marsupial. Here we provide genetic evidence establishing
that the tumor is clonal and therefore foreign to host devils. Thus,
the disease is highly unusual because it is not just a tumor but also
a tissue graft, passed between individuals without invoking an
immune response. The MHC plays a key role in immune responses
to both tumors and grafts. The most common mechanism of
immune evasion by tumors is down-regulation of classical cell
surface MHC molecules. Here we show that this mode of immune
escape does not occur. However, because the tumor is a graft, it
should still be recognized and rejected by the host’s immune
system due to foreign cell surface antigens. Mixed lymphocyte
responses showed a lack of alloreactivity between lymphocytes of
different individuals in the affected population, indicating a pau-
city of MHC diversity. This result was verified by genotyping,
providing a conclusive link between a loss of MHC diversity and
spread of a disease through a wild population. This novel disease
arose as a direct result of loss of genetic diversity and the aggres-
sive behavior of the host species. The neoplastic clone continues to
spread although the population, and, without active disease con-
trol by removal of affected animals and the isolation of disease-
free animals, the Tasmanian devil faces extinction.
conservation genetics  Tasmanian devil  wildlife disease 
immune evasion
The largest remaining marsupial carnivore, the Tasmaniandevil (Sarcophilus harrisii), is currently under threat of
extinction due to a newly emerged wildlife disease (1). Devil
facial tumor disease (DFTD) is a contagious tumor that is spread
between individuals as a rogue cell line through biting (2).
Tumors occur predominantly around the face and neck (3) and
are believed to be of neuroendocrine origin (4). During disease
progression, the tumor ulcerates, becomes friable, and affected
devils usually die within 3–6 months after the first appearance
of lesions (3), with no documented immune response. DFTD has
decreased devil numbers by 50% since its appearance in 1996,
with some populations declining by 90% (5). Although DFTD is
widespread across eastern Tasmania, it has not yet been ob-
served in northwestern populations (5).
Pearse and Swift (2) proposed that DFTD cells are transferred
between individuals as allografts, because tumor cells taken
from different individuals contain identical, complex chromo-
somal rearrangements. The immune response of devils is pro-
ficient (43), and therefore transmission of cells from one indi-
vidual to another should lead to rapid rejection of the cells by the
host immune system, due to recognition of foreign cell surface
MHC antigens.
MHCantigens are encoded by themost polymorphic set of genes
in the vertebrate genome (6) and are important for pathogen,
tumor, and graft recognition. There are two types of antigen-
presenting MHC molecules, class I and class II. Class I molecules
consist of an -chain and an associated 2-microglobulin and
present endogenous peptide antigens to cytotoxic T cells. Class II
molecules consist of an - and a -chain and bind exogenously
derived peptides for antigen presentation (7).
Class I and class II MHC genes have a highly polymorphic
peptide binding region (PBR) that enables recognition of a range
of antigenic peptides within a population (8). MHC genes are
characterized by stretches of highly conserved amino acids,
which maintain the structural integrity of the molecule, and
pockets of highly polymorphic residues in the PBR, which are
subject to positive selection (8, 9). In a population with high class
I polymorphism, grafts between unrelated individuals will be
rejected rapidly due to differences between class I alleles ex-
pressed on the surface of the donor cells and host cells.
In the presence of a functioning immune system, the failure to
recognize and targetDFTDcould be a consequence of two possible
genetic explanations. First, the tumor may ‘‘escape’’ the immune
system by modulating expression of MHC genes during tumor
growth. Second, devils may lack diversity at MHC loci, resulting in
an immune system failure to recognize the tumor as ‘‘foreign.’’
Support for these hypotheses comes from studies into other trans-
missible tumors. The canine transmissible venereal tumor (CTVT)
is passed between individuals through coitus. Although it has now
evolved into two subtypes, it originated from a single neoplastic
clone 200 years ago (10). CTVT passes across MHC barriers by
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down-regulating MHC class I and class II expression and up-
regulating nonclassical class I expression to avoid the natural killer
cell response (10).A contagious tumor has also been reported in the
Syrian hamster (11) and is thought to spread between individuals
due to a lack of MHC diversity (12).
To test the allograft theory of DFTD transmission and to
investigate the lack of immune response, we genotyped matched
tumor and host samples at microsatellite and MHC loci. We
tested the hypothesis that DFTD cells down-regulate MHC gene
expression using RT-PCR on matched tumor and host samples
and examined levels of MHC class I diversity.
Results
Microsatellite and MHC Genotyping: Proof of the Allograft Theory of
Transmission. Fifteen matched tumor and host blood samples
(Table 1) and 11 blood samples from unaffected individuals
[supporting information (SI) Table 3] were genotyped at four
previously described polymorphic microsatellite loci (13) and
MHC class I and class II loci. Tumors sampled from eight
locations throughout eastern Tasmania (SI Fig. 5) had identical
microsatellite genotypes at all four microsatellite loci, as well as
at MHC class I and class II loci (Table 1). In contrast, 88% (22
of 25) of examined devils had a unique multilocus genotype, and
in all infected devils the tumor had a genotype different from the
host (Table 1).
Tumor Cells Express Functional MHC Class I and Class II Genes.
RT-PCR experiments used RNA from matched tumor cells,
spleen, liver, and kidney samples from two affected individuals
and four additional tumor samples. These experiments demon-
strated that tumor cells express MHC class I and class II genes
(Fig. 1). The MHC class I and class II sequences expressed by
tumors were aligned with classical class I and class II sequences
from eutherian mammals, marsupials, and previously described
Tasmanian devil sequences (SI Fig. 6).
Six unique class I sequences were amplified from tumor cells
using a single primer set. These sequences show between 91%
and 99% amino acid identity to previously described devil
classical class I sequences (e.g., SahaI*01 and EF591089 from
ref. 14). Nine sites identified as important for peptide binding by
classical class I molecules (9) are present in the tumor class I
sequences, indicating a classical function (SI Fig. 6A). Cysteine
residues in the 1 and 2 domains, which form disulphide
bridges to stabilize the class I molecule, also are present in the
tumor sequences. The 25 residues that interact with the 2-
microglobulin are well conserved between the tumor sequences
and marsupial class I genes. We have previously shown that the
Tasmanian devil has at least five classical and two nonclassical
class I genes (14). Nonclassical class I sequences exhibiting
tissue-specific expression patterns, a lack of polymorphism, and
phylogenetic distinctness from classical devil class I genes (14)
were not expressed by the tumor. The six amplified alleles
probably account for the five classical loci, with only one locus
being heterozygous.




samples Location Sh2g Sh2l Sh3a Sh3o Class I 1 Class I 2 Class II 1
T0858 B0858 Bothwell (1) 0,4 (0,0) 2,2 (2,2) 0,0 (0,2) 2,2 (0,2) 1 (1) 1 (1) 1 (2)
T1277 B1277 Forestier (2) 0,4 (0,0) 2,2 (2,2) 0,0 (0,2) 2,2 (0,2) 1 (4) 1 (1) 1 (1)
T1926 B1926 Weegana (3) 0,4 (0,0) 2,2 (—) 0,0 (—) 2,2 (2,2) 1 (2) 1 (1) 1 (—)
TC1926 Weegana (3) 0,4 2,2 0,0 2,2 1 1 1
T2024 B2024 Forestier (2) 0,4 (0,6) 2,2 (2,2) 0,0 (0,2) 2,2 (0,2) 1 (5) 1 (1) 1 (2)
T2027 B2027 Forestier (2) 0,4 (0,0) 2,2 (2,2) 0,0 (0,0) 2,2 (0,2) 1 (4) 1 (3) 1 (4)
T2772 B2772 St. Marys (4) 0,4 (0,2) 2,2 (2,2) 0,0 (0,0) 2,2 (2,2) 1 (1) 1 (1) 1 (3)
T2107 B2107 Forestier (2) 0,4 (0,6) 2,2 (2,2) 0,0 (0,2) 2,2 (2,2) 1 (3) 1 (1) 1 (3)
T2891 B2891 St. Marys (4) 0,4 (0,0) 2,2 (0,2) 0,0 (0,0) 2,2 (0,0) 1 (5) 1 (1) 1 (4)
T1857 B1857 Railton (5) 0,4 (0,6) 2,2 (0,2) 0,0 (2,2) 2,2 (2,2) 1 (1) 1 (1) 1 (4)
T2734 B2734 St. Marys (4) 0,4 (0,0) 2,2 (2,2) 0,0 (0,2) 2,2 (0,0) 1 (4) 1 (2) 1 (4)
T2336 B2336 Narawntapu (6) 0,4 (0,4) 2,2 (2,2) — (0,2) 2,2 (2,6) 1 (4) 1 (2) 1 (4)
T1363 B1363 Forestier (2) 0,4 (0,0) 2,2 (2,2) 0,0 (0,0) 2,2 (2,2) — (—) — (—) 1 (—)
T2021 B2021 Forestier (2) 0,4 (0,0) 2,2 (2,2) 0,0 (0,2) 2,2 (0,2) 1 (4) 1 (1) 1 (2)
T2671 B2671 Buckland (7) 0,4 (0,4) 2,2 (2,2) 0,0 (0,2) 2,2 (2,2) 1 (2) 1 (1) 1 (1)
T2673 B2673 Buckland (7) 0,4 (0,4) 2,2 (2,2) 0,0 (—) 2,2 (0,2) 1 (5) 1 (1) — (2)
TC3089 Bronte Park (11) 0,4 2,2 0,0 2,2 1 1 1
TC385 Forestier (2) 0,4 2,2 0,0 2,2 1 1 1
T1440 Forestier (2) 0,4 2,2 0,0 2,2 1 1 1
T416 Forestier (2) 0,4 2,2 0,0 2,2 1 1 1
Genotypes of 15 matched tumor/blood samples, 2 additional tumor samples, and 2 DNA samples derived from tumor culture for microsatellite, as well as MHC
class I and class II loci. T, tumor biopsy; TC, cultured tumor cells; B, blood sample; —, data not available. For each microsatellite locus, the smallest allele was
designated 0, with additional alleles numbered according to their increasing base pair length. SSCP on MHC class I 1 and2 and class II1 were scored according
to banding patterns from 1 to 6. The values for tumor and DNA data are given, with the values for the blood samples shown in parentheses, except under Location,
where the numerals in parentheses correspond to the geographic distribution of collection localities indicated in SI Fig. 5. Additional genotypes of animals that
were not diseased are located in SI Table 3.
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Fig. 1. RT-PCR showing expression of MHC class I (A) and class II (B) genes by
matched tumor, liver, spleen, and kidney samples. T, tumor biopsy; S, spleen;
L, liver; K, kidney; N, negative control; M, marker.
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Four unique class II DAB sequences, representing at least
two loci, are expressed by the tumor cells and show between
96% and 100% identity to previously characterized DAB
sequences (SI Fig. 6B) (14). The class II sequences amplified
from the tumors contain a cysteine bridge, an RFDS motif for
CD4 binding and an NGT glycosylation site in the 1 domain
(15). Prior studies have shown that a tryptophan residue and
an asparagine residue, located in the 1 domain, are important
for peptide binding (SI Fig. 6B) (15), yet all tumor samples
express sequences in which the tryptophan residue is substi-
tuted for a lysine residue. Although, a substitution at this
position is rare, it has been observed in other marsupials (16),
and its effects on antigen binding are unknown.
Low Polymorphism at MHC Class I Loci. Two approaches were taken
to investigate levels of polymorphism in devil MHC genes. First,
allogeneic responses were analyzed in vitro by using mixed
lymphocyte reactions. Lymphocytes from 30 eastern Tasmanian
devils were pooled and tested against each other as well as
serving as target cells for lymphocytes from a range of eastern
devils, including a northern and an island population (SI Fig. 5).
No mixed lymphocyte responses were observed with any of these
cultures (Fig. 2 and SI Table 4). Strong proliferative responses
were observed when Con A was used as a mitogen, providing an
effective positive control confirming that the cells could prolif-
erate when provided with an appropriate stimulus. Because
marsupials demonstrate low allogeneic responses (17, 18), two-
way mixed lymphocyte reactions were performed by using the
lymphocytes from two unrelated eastern quolls (Dasyurus viver-
rinus). Like the Tasmanian devil, the eastern quoll is a dasyurid
marsupial and shares a similar habitat. When compared with the
devil and assessed after 96 h of culture, the two-way mixed
lymphocyte responses of the quoll lymphocytes was 20 times
more effective than the mixed lymphocyte reaction of the pooled
devil lymphocytes (Fig. 2). However, these responses were still
not equivalent to mitogen stimulation.
Molecular typing at MHC loci of 21 devils and 19 tumors using
single-strand conformation polymorphism (SSCP) identified six
class I 2 domain types, six class I 1 domain types, and five class
II 1 domain types (Table 1 and SI Table 3). SSCP was
performed on the class I 1 and 2 domains separately, these
domains were chosen for analysis because they encompass the
PBR of the molecule. Of host blood samples, 78% had an
identical SSCP pattern for the class I 2 domain as the tumor,
25% were identical to the tumor at the 1 domain, and 14% had
an identical SSCP pattern for class II 1 as the tumor (Table 1);
however, no hosts had an identical MHC type to the tumor at
both class I and class II loci. Individuals with unique MHC types
were selected for sequencing. Allele sequencing identified 26
unique class I 1 sequences (Fig. 3A and SI Fig. 7A) and 16
unique class I 2 sequences (Fig. 3B and SI Fig. 7B). These
alleles were amplified with multilocus primers (14). Because of
the high level of sequence similarity between the devil class I loci,
it was impossible to design locus-specific primers, and estimates
of class I variation are based on multiple loci. All predicted
molecules appear to be capable of peptide binding. Very low
amino acid diversities are found in the 2 domain (15% maxi-
mum and 14% average amino acid variation) and 1 domain
(21% maximum and 16% average amino acid variation).
We used residues in the PBR, identified as highly polymorphic
in human and mouse (6, 19), to compare polymorphism in devils,
humans, and Gir lions (Panthera leo persica) (n  25), a wild
population that has undergone severe historical population
reduction. The devil sequences showed far fewer substitutions at
polymorphic residues than has been found in similar studies on
lion and human (Fig. 4 and SI Table 5). Within the class I
sequences, only 13 of a possible 38 PBR residues are polymor-
phic, and only two sites in the PBR have more than two
substitutions.
Z tests for positive selection were performed on the 1 and 2
domains of the class I sequences at PBR sites and non-PBR sites
(Table 2). In the 2 domain, there was no significant difference
in the number of nonsynonymous to synonymous substitutions,
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Fig. 2. Mixed lymphocyte reaction and Con A stimulation of lymphocytes
from 30 devils and 2 eastern quolls obtained from the same region of Tasma-
nia. Due to the limited amount of blood that could be collected from the
quolls, only a single (96 h) time point was possible. To confirm that the devil
lymphocytes could proliferate, Con A was added at a final concentration of 50
mg/ml.
Fig. 3. Amino acid alignments of class I 1 and 2 domains from devils. (A)
Amino acid alignment of unique class I 1 domain sequences from devils.
Orientation of the residues in the molecule is indicated below the sequence as
follows; asterisks, residue points toward the peptide binding site; plus sign,
residue is on the-helix pointing upward toward the binding site; dot, residue
is on the -helix pointing away from the peptide binding site. (B) Amino acid
alignment of unique class I 2 sequences from devils. Orientation of the
residues in the molecule is indicated below the sequence as in A.






non-PBR sites. The PBR sites in 1 domain had an excess of
nonsynonymous to synonymous substitutions, and a Z test
indicated positive selection at PBR sites.
The class I 1 and 2 sequences amplified from the hosts were
compared with the class I sequences expressed by the tumor
cells. Expressed class I sequences spanning multiple domains
were not amplified from the hosts, so comparisons were made by
using the 1 domain and 2 domain separately. Five of the six
tumor class I 1 sequences were found in one or more devil
hosts; indeed, the 1 domain of tumor allele 3297T*4 was found
in every devil examined. All tumor 2 domain sequences were
found in one or more devil, which is unsurprising, because this
domain had extremely low variation.
Discussion
Here we provide conclusive multilocus genetic evidence for the
allograft theory of DFTD transmission, confirming that this
disease is a clonal rogue cell line. We demonstrate that altered
MHC expression, a common cause of immune evasion by tumors
(20), is not responsible for a lack of immune response to DFTD,
and we suggest that low MHC diversity in the devil has enabled
natural transmission of tumor cells between individuals.
Although90% of sampled devils were genetically unique, all
examined devil facial tumors had an identical genotype at
multiple microsatellite and MHC loci, substantiating the clonal
nature of the tumor. In addition, the tumor genotype was
different from that of all examined host devils (Table 1),
verifying that the tumor cells are not ‘‘self,’’ but came from an
external source. DFTD is only the second naturally occurring
transmissible tumor to be described. The only other naturally
occurring transmissible tumor, CTVT, has evolved into geneti-
cally distinct subtypes over time and is essentially a nonfatal
‘‘parasite’’ in dogs (10). Although we found no evidence of
differences in DFTD genotypes, it is important to note that the
CTVT cell line is at least 200 years old (10), whereas the DFTD
cell line emerged recently, 10 years ago (5). DFTD may, with
time, evolve into a less lethal form, but maintaining devil
numbers in the meantime will be difficult (1).
Many tumors, including CTVT, avoid immunological recog-
nition by down-regulating classical class I (class Ia) expression
and up-regulating nonclassical class I (class Ib) expression (10,
21, 22). By expressing class Ib molecules, tumor cells avoid
recognition by natural killer cells and escape immune recogni-
tion by T cells (22). Immune evasion by DFTD does not occur
due to an alteration in MHC gene expression. We showed that
DFTD tumors express at least three, possibly all five, class Ia loci
and do not express any class Ib loci. Surprisingly, the tumors,
which are believed to be of neuroendocrine origin (4), express
class II molecules. Class II molecules are usually only expressed
on hematopoietic and thymic cells, including monocytes, mac-
rophages, and B cells (23). Histological analysis of DFTD has
clearly shown that T lymphocytes do not infiltrate the tumor or
the metastases to draining lymph nodes, despite the expression
of MHC class I and MHC class II on the tumor cells (3, 4).
Consequently, T cells are not activated by the tumor itself or by
tumor cells within the lymph nodes. Expression of functional,
classical MHC molecules by DFTD cells, with no evidence of an
immune response to the foreign tumor, is highly unusual and
suggests that an alternative explanation exists for the ability of
DFTD to pass between individuals as a graft.
Cytokines within the microenvironment of the tumor may play
a role in tumor evasion. In CTVT, TGF-1 plays a major role in
helping the tumor evade the host response (24). Characterization
of cytokine profiles during tumor growth should be conducted;
however, it seems unlikely that the tumor secretes a potent
suppressive factor that limits lymphocyte activation, because the
culture supernatant obtained from DFTD cultures does not
inhibit mitogen-induced lymphocyte proliferation (SI Fig. 8).
We therefore propose that a lack of MHC diversity in the devil
is the most likely explanation that has enabled natural transmis-
sion of tumor cells, with foreign cells seen as ‘‘self’’ rather than
‘‘non-self.’’ Pioneering studies by O’Brien and colleagues (25)
demonstrated that a lack of graft rejection between unrelated
cheetahs (Acinonyx jubatus) and the subsequent acceptance of
foreign grafts was due to a lack of MHC diversity, the result of
an ancient genetic bottleneck followed by inbreeding (25). These
samples were not genotyped, although later studies confirmed
low levels of class I diversity in cheetahs (26). Similarly, graft
acceptance can occur between immunocompetent pocket go-
phers (Thomomys bottae), where MHC diversity is low (27). The
combination of MHC genotyping and an absence of alloreac-
tivity against non-self MHC antigens between individuals in
mixed lymphocyte reactions indicates that the devil is unable to
mount an immune response to DFTD due to depleted MHC
diversity.
Devil class I sequences show less variation at class I loci than
is found in other species, including humans, mice, and even the
inbred Gir lions (Fig. 4) (20). The devil class I 2 sequences have
only 14% average amino acid variation across multiple loci
compared with 41% in only 10 Gir lions across multiple loci (20).
At the 1 domain, the average variation for the devil sequences
is 16% compared with 40% in the Gir lions. A lack of variation
in the devil class I sequences also extends to the usually
polymorphic PBR. The low levels of class I diversity in the devils
and the high level of similarity between tumor and host types is
further highlighted by the fact that all but one of the sequences
expressed by the tumor are found in at least one host and that
one class I sequence is found in all of the tumor and hosts
samples.
An absence of mixed lymphocyte responses between devils
























Fig. 4. Graphical representation of polymorphism in the PBR of class I
sequences from humans (HLA-A, HLA-B, and HLA-C) (19), wild Gir lions (mul-
tiple loci) (n  25), and Tasmanian devils (multiple loci) (n  25). The y axis
shows the number of substitutions at polymorphic residues involved in pep-
tide binding. The x axis shows the amino acid position according to Bjorkman
and Parham (19).
Table 2. Summary of synonymous (dS) and nonsynonymous (dN)
substitutions for class I 1 and 2 domains
Domain N dN dS Z statistic P
1
PBR sites 18 0.144 0.044 1.925 0.028
Non-PBR sites 24 0.014 0.004 0.952 0.172
2
PBR 20 0.034 0.010 0.903 0.184
Non-PBR sites 36 0.029 0.021 0.399 0.345
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Tasmania have functionally identical MHC haplotypes. How-
ever, it should be noted that two other marsupials have docu-
mented weak mixed lymphocyte responses; the gray short-tailed
opossum (Monodelphis domestica) (18) and the koala (Phasco-
larctos cinereus) (28). These studies prompted suggestions that
the marsupial immune system is ‘‘immunologically lazy’’ or at
least different from that of eutherians. To ensure reliability of
assay conditions in the current study, positive controls, using a
related carnivorous marsupial, the eastern quoll (Dasyurus viver-
rinus), were used. Quolls were found to have allogeneic re-
sponses markedly superior to those of devils. Furthermore, devil
lymphocytes responded extremely well to mitogen stimulation
(43), suggesting that failure to respond in the allogeneic assays
was due to a failure of activation rather than an inability to
proliferate. The limited genetic diversity at MHC loci and a lack
of mixed lymphocyte responses strongly supports our hypothesis
that the tumor is able to avoid the immune system due to a lack
of diversity inMHC genes. However, conclusive evidence for this
will only come from skin-grafting experiments, which are the
most accurate measures of genetic immunological identity (25).
This study provides a direct link between disease susceptibility
and low MHC class I diversity in a wild population (29). Low
MHC class I diversity has been reported for cheetahs (25), the
Hawaiian monk seal (Monachus tropicalis) (30), and some spe-
cies of whales (i.e., Balaenoptera physalus and Balaenoptera
borealis) (31); however, links with specific diseases have not been
established. DFTD is a transmissible tumor that spreads through
a population due to a lack of histocompatibility barriers. The
disease has progressed rapidly due to low diversity at MHC loci
and the propensity of devils to bite each other around the face
and mouth during mating and fights for food (32). Murgia et al.
(10) suggested that CTVT first arose in an inbred dog or wolf
population, because MHC class II loci are homozygous in
tumors, whereas the two class I alleles are highly similar. It is
possible that CTVT evolved in much the same way as DFTD, yet
over time CTVT has developed strategies to regulate cell-surface
MHC expression to allow passage to MHC disparate animals.
The Tasmanian devil has undergone several population fluc-
tuations over the last 150 years (33) and has low genetic diversity
at microsatellite and MHC loci (13). Populations restricted to
islands generally have reduced genetic variation (34) and are
believed to be more vulnerable to novel environmental stresses
(35), including disease (36). This study provides a frightening
example of the potential consequences of loss of genetic diversity
in a region of the genome that is vital for self/non-self recogni-
tion as well as disease resistance. These findings reinforce the
need for conservation biologists to focus on genetic diversity at
functionally important loci that play a role in population fitness
when designing conservation strategies. For devils, ensuring
maximumMHCdiversity in insurance populations is paramount.
In light of the devils inability to recognize the clonal facial
tumors as foreign and mount an immune response, the only
course of action is the isolation of unaffected animals and the
ongoing removal of affected animals from the population.
Materials and Methods
Sample Collection and Processing. Mixed lymphocyte response experi-
ments. Animals were anesthetized with isofluorane delivered via
mask in an open system, and 8–10 ml of blood was taken from
the jugular vein in lithium-heparinized tubes (ethical approval
was given by the Animal Ethical Committee of Tasmania’s Park
and Wildlife Services under no. 33/2004-5 and 32/2005-6).
Mononuclear cells were isolated in a gradient (Histopaque 1077;
Sigma, St. Louis, MO), centrifuged, washed with RPMI medium
1640 (JRH Biosciences, Lenexa, KS) containing 100 units/ml
gentamicin and 2 mM glutamine, and diluted to a concentration
of 106 cells per milliliter.
RNA and DNA extraction from blood and tissue.DNA extractions were
conducted by using the Wizard Genomics DNA purification kit
(Promega, Madison, WI) and RNA extractions using TRIzol
reagent (Invitrogen, Carlsbad, CA). Blood (300 l) and 40 g
of tumor were used in the extraction process. Sample concen-
trations were measured by using a GeneQuant spectrometer
(Amersham Pharmacia Biosciences, Little Chalfont, U.K.).
RT-PCR on MHC Class I and Class II by Tumor Cells. RNA (1 g) was
reverse transcribed by using the SuperScript III reverse tran-
scription kit (Invitrogen). MHC class I and II sequences were
amplified with primer sets 3 and 5 (SI Table 6), respectively, from
two matched tumor, liver, kidney, and spleen samples and an
additional four tumor samples. Class I and class II sequences also
were amplified from tumor cell culture to ensure that there was
no contamination of tumor RNA with host RNA. Amplification
with primer sets 3 and 5 occurred in 1 buffer, 2 mMMgCl2, 200
M dNTP, each primer at 2 M, and 0.3 l of Taq polymerase
(Invitrogen). The PCR cycling conditions were as follows: initial
denaturation at 94°C for 3 min, followed by 35 cycles of 94.0°C
for 30 s, 63°C for 1 min, and 72°C for 1 min, and a final extension
at 72°C for 10 min. -actin was used as a positive control (data
not shown). Positive gel bands were purified (UltraClean DNA
purification kit; MO BIO Laboratories, Carlsbad, CA) and
cloned into a PGEM T-EASY vector (Promega). Twenty clones
were sequenced in both directions from each sample.
Microsatellite Typing of Tumors and Host. Fifteen matched tumor/
blood samples, 2 additional tumor samples, 2 DNA samples
derived from tumor culture, and 11 blood samples from unaf-
fected individuals were genotyped by using themicrosatellite loci
Sh2g, Sh2l, Sh3a, and Sh3o (13), following the PCR conditions
of Jones et al. (13) and visualized as previously described (37).
SSCP on Class I MHC Loci. SSCP was performed on the samples
described above by using primer sets 1, 2, and 4 (SI Table 6).
Amplification for primer sets 1, 2, and 4 occurred in 1 buffer,
2 mM MgCl2, 200 M dNTP, each primer at 2 M, and 0.3 l
of Taq polymerase (Invitrogen). Cycling conditions for primer
sets 1 and 2 were as follows: initial denaturation at 94°C for 3
min, followed by 35 cycles of 94°C for 30 s, 63°C for 1 min, and
72°C for 1 min, and a final extension at 72°C for 10 min. Cycling
conditions for primer set 4 were as follows: initial denaturation
at 94°C for 3 min, followed by 35 cycles of 94°C for 30 s, 57°C for
1 min, and 72°C for 1 min, and a final extension at 72°C for 10
min. SSCP was performed according to the protocol put forth by
Sunnucks et al. (38).
Sequencing MHC Class I Alleles. Individuals with unique SSCP
patterns for MHC class I 1 and 2 domains were identified, and
the class I 1 and 2 domains of these individuals were amplified
separately by using primer sets 1 and 2 under the conditions
described above. Positive gel bands were gel-purified and se-
quenced as described above.
Sequences were edited and quality-checked with Sequencher
4.1.4 (Gene Codes, Ann Arbor, MI) and BioEdit (39). To
estimate PCR and cloning error, we performed independent
PCRs on two individuals and sequenced 25 clones from each
individual. We estimated that 10% of clones sequenced con-
tained at least 2 bp of cloning error. This figure is more
conservative than has previously been reported in the literature
(40). Clustal W was used to align sequences, with some manual
adjustments (41). The number of synonymous mutations per
synonymous site and the number of nonsynonymous substitu-
tions per nonsynonymous site were calculated by using Mega 3.1
(42). Mega 3.1 also was used to test for positive selection in PBR
and non-PBR residues separately using the modified Nei–






Gojobori method with Jukes–Cantor adjustment for multiple
substitutions at a single site.
Mixed Lymphocyte Responses. Blood from 30 Tasmanian devils
from different regions of eastern Tasmania, Australia (SI Fig. 5)
was collected, and mononuclear cells were isolated as described
above and frozen in a solution of 10% DMSO and 90% FCS at
80°C. When required, cell suspensions were thawed, pooled,
and diluted to a concentration of 106 cells per milliliter.
Mixed lymphocyte reactions were performed in 96 U-
bottomed-well plates in triplicate and incubated from 72 to 168 h
at 37°C and 5% CO2. A pool of plasma from 10 healthy
Tasmanian devils was used as a supplement for the cell culture
in all experiments. Cells were pulsed with 1 Ci of [methyl-
3H]thymidine (Amersham Pharmacia Biosciences) 18 h before
harvesting onto a glass-fiber filter paper, and radiation uptake
was counted in an automated scintillation counter (LKB–Wallac,
Turku, Finland). Results are expressed as cpm or stimulation
index, where the stimulation index is the average cpm obtained
from the mixed lymphocyte reaction divided by the average
background cpm of effector cells alone. As a control for the cell
viability and proliferative capacity, cells were incubated with
ConA at 50g/ml (ConA; Sigma), and the stimulation index was
calculated as described above. In addition, a two-way mixed
lymphocyte reaction was performed with lymphocytes from two
eastern quolls. Eastern quoll pooled plasma was used as a
supplement for the cell culture and incubated for 96 h. Other
incubation conditions were as described above.
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